Introduction: ocular surface disease (oSd) is a major cause of ophthalmological consultation. Within this group, glaucoma patients constitute an important percentage due to the nature of their chronic topical treatment. advances in the understanding of ocular surface pathology on both a cellular and molecular level, and the interaction to the toxic nature of some topical medication solution compounds, are stimulating the development of better alternatives in topical treatment. Materials and Methods: Extensive review of available literature and current research on topical ophthalmological treatments in both oSd and glaucoma was performed. Emphasis was made on inflammatory modulators of the ocular surface and pathological changes associated with the use of preservatives in solutions, in particular benzalkonium chloride (BaK). independent research is been also performed by the authors, using a rubbing-induced reflex tears collecting method with capillary tubes. cytokines in tear samples were subsequently analysed with the multi-Plex System (luminex ® R-200). The 12 cytokines analysed using this method are the interleukins (il)-1β, il-2, il-4, il-5, il-6, il-7, il-8, il-10, il-12, the tumour necrosis factor alpha (TNFα), the vascular endothelial growth factor (VEGF), the granulocyte-macrophage-colony stimulating factor (GM-cSF) and the interferon gamma (iFg). Results: our unpublished, preliminary results trend to show higher values in il-5 and il-6 in glaucoma patients than in normal controls. also, higher values in il-2, il-5 and il-12 in dry eye syndrome (dES) patients were found versus normal controls. Conclusions: inflammation is an important element in oSd and strong association seems to exist between this and the use of BaK preservative. New kinds of preservative molecules, as well as single-dose eye drops and sophisticated dispensing bottle mechanisms, are currently available on the market in order to avoid the secondary effects of this topical treatments, increasing patient compliance and adherence to chronic topical glaucoma treatment.
is an elevated intraocular pressure (iop). Glaucoma constitutes the first cause of blindness in Europe and one of the main causes worldwide. 7 the first line of treatment typically constitutes topical medical treatment that either decrease aqueous humor production and/or facilitates its outflow. Just as with many eye drops, these medications generally contain preservatives to warranty their safety. recent evidence has showed that some of the ingredients used as preservatives in many ophthalmic medications, (even some for the treatment of DES), are at least partially responsible for the problem. 8 in particular, glaucoma patients, who are exposed to a chronic use of preservatives in their treatment, represent a very susceptible population.
Preservatives and Effects
the most commonly used preservative in ophthalmic preparations is benzalkonium chloride (BaK). 8 it is a nitrogenous cationic surfaceacting agent belonging to the quaternary ammonium group.
Quaternary ammoniums are bipolar compounds which are highly hydrosoluble and have surfactant qualities. they behave as detergents, dissolving microbial cell walls, thus, they function as preservatives for ophthalmic solutions. the problem comes from this same detergent effect acting upon the ocular surface. there is a delicate balance in the homeostasis of the tear film and cellular function within both conjunctiva and cornea. it is well known that deficient tear production, abnormal tear quality (tBut) was present in 78 % of patients.
another large-scale study was carried out on a population of 4,107 patients measuring the incidence of ocular toxicity from glaucoma medications. 15 Eighty-four per cent of the patients used preserved eyedrops. ocular symptoms were much more evident in patients taking preservative solutions compared to those using preservative-free medications (p<0.001). the symptoms included, itching, foreign-body sensation, eyelid itching, tearing and burning. patients on the preserved eyedrops had a more than twofold presence of these symptoms. ocular signs and symptoms, as one can expect, increased directly proportional to the number of preserved solutions applied by the patient.
in Europe, a multicentre epidemiologic study was carried out to compare the presence of side effects in about 10,000 patients on a topical either preserved or non-preserved beta-blocker. 16 ocular side effects, such as discomfort upon instillation, itching, foreign-body sensation or burning, were significantly more frequent in the preservative-medication group (p<0.0001). the most commonly used preservative at that time was BaK.
the relatively high incidence of oSD among glaucoma patients is clearly noticed when comparing it to the presence of dry eye in the normal population. a cross-sectional survey among 25,444 men in the uS found that the prevalence of DES increased with age from about 3.9 % among men aged 50-54 years, to 7.7 % on those aged >80 years. 17 another survey performed on 40,000 women in the uS reported 5.7 % of women <50 years old suffered DES symptoms, compared to 1. Drug-related allergic reactions, in most clinical trials it remains as a relatively rare situation, happening mostly in the early course of treatment, affecting a few per cent of patients and mainly consisting of an acute conjunctivitis-like reaction (see Figure 2) . From the different formulations, latanoprost eyedrops showed ocular allergic reactions in only 1.5 % of patients. 21 higher rates of ocular allergy (13.5 %) have been found on brimonidine eyedrop treatment (mean time of occurrence after initiation of around 15 days). 22 But, other clinical manifestations could be related to drug toxicity, e.g. corneal punctuate staining, without involving any allergic reaction. 23 So, it is important to discriminate early, acute allergic reactions from other more delayed toxic and non-specific inflammatory mechanisms.
2. periocular dermatitis -as Baudouin refers, 20 in addition to allergic conjunctivitis, (which rarely corresponds to type i hypersensitivity) the most frequent drug-induced allergic reaction is a type iV delayed cell-mediated hypersensitivity. this could explain why many reactions occur at the eyelid level, (such as allergic blepharitis) which are often difficult to distinguish from other causes of eyelid inflammation or contact dermatitis (see Figure 3) . there are even some reported cases which present with an atypical lichenoid eruption. So, it seems we still lack strong evidence to support this hypothesis;
anyway, all previous pathological studies cited in the paper and more recent molecular analysis oriented studies [34] [35] [36] are consistent with the fact that the conjunctiva of glaucoma patients is affected with this subclinical inflammation after a certain time of medical treatment, and that this could in turn influence the success of future filtration surgical treatments.
Materials and Methods -Preliminary Research by the Authors
as mentioned earlier in this article, much work has been done in recent years to develop a practical system to analyse tear film molecules associated with inflammation and with DES. the luminex multi-analyte profiling assay system (labmap, austin, tX) is an outstanding new technology based on flow citometry. 37 a major characteristic of this system is that it permits a wide spectrum of measuring procedures, ranging from one single determination to simultaneously assaying various analytes.
another main advantage is that very small sample volumes can be utilised.
it has recently been demonstrated that the luminex system is useful in analysing cytokine levels in human tears collected with capillary tubes 38 or by Schirmer test strips. 39 our main goal is to study and compare tear cytokine/chemokine concentrations in Glaucoma patients under medical treatment, DES patients and control individuals to determine changes in immune-response and inflammation mediators.
We used a gentle rubbing-induced reflex tears collecting method with capillary tubes for specimen collection (see Figure 4) . reflex tears were 
Conclusions -Practical Implications in Glaucoma Management
medical topical treatment of glaucoma is generally the first line of management, applied either as a unique treatment or in combination with surgery and/or laser during the course of the glaucomatous disease. Because of this and of the chronic nature of the disease, medical hypotensive treatment should be considered as a longterm requirement. Besides, medical treatment is typically carried out on a combined medication scheme. 48, 49 the ultimate purpose of efficient glaucoma management is preserving visual function, while sustaining good quality of life at a reasonable cost. this is empowered by avoidance of secondary effects and inconvenience of the topical medications. 50 it is known that patients with higher rates of secondary effects and worse quality of life, are those recognising to have poor adherence to treatment regime. 51 the impact of a lack of adherence to glaucoma treatment on its evolution has not yet been determined, but it seems reasonable to suggest that low adherence to treatment has important detrimental effects on the visual prognosis and general disease control. in order to increase adherence, simplification of therapeutic regime is essential, just as decreasing the secondary effects of medication; in fact, bad local tolerance has been described as the third major cause of non-adherence after forgetfulness and inadequate dose administration.
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Alternatives to Benzalkonium Chloride the only way to totally eliminate BaK-related side effects, especially in the most sensitive patients, would obviously be to remove BaK from eye drops; however, this raises industrial and regulatory concerns. 8 Singledose units are the most frequently used preservative-free preparations and depending on the country, some compounds are available such as tafluprost, a prostaglandin analogue, and most of the others consisting in different beta-blockers; this, mainly because they were the first active ingredients to became generics and could more easily be re-developed by the industry in a single-dose, preservative-free form.
however, some drawbacks have been pointed out regarding singledose units, such as higher cost and difficult handling, especially in elderly patients. 54 other study conclude that patients could manage single-dose units as least as well as the conventional eye drop bottles. 55 anyway, multidose bottles have been developed, working by either allowing the preservative filtration and posterior absorption on a porous membrane, or by using a valve system that hinders penetration of bacteria into the bottle. the aBaK ® (laboratoires théa, France) and comoD ® (ursapharm, Germany) are examples of these systems, and have been patented and commercialised with various beta-blockers such as timolol, carteolol and non antiglaucomatous compounds. [56] [57] [58] particularly, the aBaK ® (thea laboratories, France) system contains a 0.2 micron nylon fibre membrane that filters the solution. the pressure exerted causes the solution to pass through the antibacterial filter in the aBaK ® system, forming a drop that falls from the tip of the dispenser. When pressure is released, the solution is re-absorbed and filtered from bacteria and air, ensuring the protection of the solution throughout its use. hence, the aBaK ® system filter provides a double protection from microbial contamination without using preservatives.
Extensive research has been conducted to develop less toxic preservatives than BaK and quaternary ammoniums. 8 as a conclusion, given that glaucoma is a non-curable sight-threatening disease and that its effective control relies mainly on chronic topical treatment with good patient adherence to the prescribed medical regimen, minimisation of ocular surface side effects is essential.
alternatives for eye-drops that avoid harming ocular surface and simultaneously act effectively in lowering intraocular pressure, are crucial milestones for ideal glaucoma management. n
